Publications

Skip to content

Publications

Explore Flatiron-authored research

Analysis of real-world progression and insufficient response variables and related endpoints among patients with non-Hodgkin lymphoma

Advances in Therapy

Richey M, Fullerton C, Zhang Q, et al

March 2025

publication-summary-analysis-of-real-world-progression-with-insufficient-response-variables-and-related-endpoints-among-patients-with-non-hodgkin-lymphoma

1,800 publications—and counting

To date, over 1,800 publications—authored by either Flatiron or our partners—have used Flatiron’s real-world data

Explore a list of all publications

See the impact of our data

Database Characterization Guide

An overview of Flatiron Health EHR-derived US data for journal reviewers and readers to better understand the data used in publications

Review our guide

Explore our summaries of Flatiron-authored research

Disease area

Acute myeloid leukemia

Breast cancer

Chronic lymphocytic leukemia

Colorectal cancer

Diffuse large B-Cell lymphoma

Gastric/Esophageal cancer

Head and neck cancer

Hepatocellular carcinoma

Melanoma

Metastatic breast cancer

Multiple myeloma

Non-small cell lung cancer

Ovarian cancer

Pancreatic cancer

Prostate cancer

Renal cell carcinoma

Small cell lung cancer

Tumor agnostic

Urothelial cell carcinoma

Topics

Comparative effectiveness

Drug discovery

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Prospective study

Quality improvement

Quality reporting

Regulatory

Resistance ID

Treatment patterns

Unmet need

Showing 9 of 0 results

Blood Cancer Journal
December 2025
Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies
Taylor L, Chen A, Pierre A.
SABCS
December 2025
Real-world glucagon-like peptide-1 use and association with clinical characteristics, social determinants, and circulating tumor DNA positivity in patients with breast cancer
Ryals C, Blarre A, Adamson B, et al.
SABCS
December 2025
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024
Meisel J, Pham T, Chen C, Kris A, Roose J
- Publication summary
- Publications
SABCS
December 2025
Real-world progression-free survival 2 and tumor response with CDK4/6is + aromatase inhibitor in patients with HR+/HER2– metastatic breast cancer
Rugo H, Brufsky A, Layman R, et al.
SABCS
December 2025
Real-world treatment patterns in 1954 US patients with HER2-negative early breast cancer and germline BRCA mutations (2021–2025)
Sardesai S, Ru M, Ma X, et al.
SABCS
December 2025
Racial/ethnic inequities in access to novel therapies and outcomes in triple negative breast cancer
Mbah O, Ho G, Keane C, Dolor A, Ryals C.
SABCS
December 2025
Real-world overall survival with palbociclib plus an aromatase inhibitor in patients with HR+/HER2− metastatic breast cancer who are overweight/obese
Brufsky A, Iyengar N, Liu X, et al.
ESMO AI & Digital Oncology
November 2025
Privacy-preserving error analysis loop For ML-based extraction of oncology EHR data
Groizard L, Dolezalova N, Kushnir M, et al.
ESMO AI & Digital Oncology
November 2025
Structuring GDPR-compliant private networks to enable LLM-Extracted oncology data on pseudonymized patient EHR data in Europe
Ellsworth L, Groizard L, Stefan F, et al.

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Cookie Settings
© FLATIRON HEALTH® 2025